Latest Breaking News On - Ute dugan - Page 1 : vimarsana.com

LumaBridge and Parker Institute for Cancer Immunotherapy Announce Strategic Alliance to Streamline Immunotherapy Development

Stock Market | FinancialContent Business Page

Stock Market | Daily Herald

BioSpace Movers & Shakers, Feb. 19

Published: Feb 19, 2021 By Alex Keown PICI – Bristol Myers Squibb veteran Ute Dugan was named Senior Vice President of Clinical Research at the Parker Institute for Cancer Immunotherapy (PICI). She will oversee PICI’s clinical development, regulatory affairs and translational medicine efforts, with a focus on overcoming immunotherapy resistance and advancing novel breakthrough treatment combinations. At BMS, she was head of Worldwide Oncology External Medical Affairs, where she created research collaboration models to advance immune-oncology treatments together with partners in academia, professional societies and non-profit organizations. Dugan originally joined BMS as executive director of Global Clinical Research during the formation of the development teams for the pioneering I-O medicines ipilimumab and nivolumab. Before that, her career included stints at Roche/Genentech and Aventis.

New Global Coalition Aims to Eliminate Structural Barriers to Fight Cancer Crisis in Resource-Limited Countries in Africa

New Global Coalition Aims to Eliminate Structural Barriers to Fight Cancer Crisis in Resource-Limited Countries in Africa Share Article Collaboration on Implementation Science Research in Global Oncology awards $500,000 to eight country-specific pilot projects in quest to develop sustainable best practices We have to look across the spectrum of cancer care capacity building and select certain projects to pilot in different countries, evaluate how they work and, if we, can replicate them in other countries,” said Ute Dugan, MD, co-founder of CIRGO. CHICAGO (PRWEB) February 09, 2021 A group of global oncology organizations have joined forces to establish the Collaboration on Implementation Science Research in Global Oncology (CIRGO) to improve the coordination of cancer care systems in low- and middle-income countries, particularly in Africa.